Hans E. Purkey

Hans E. Purkey

Auto-generated profile, based on publicly available information

Hans E. Purkey

Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2014 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ZTZhi-Fu Tao
Zhi-Fu Tao
LHLisa Hasvold
Lisa Hasvold
LWLe Wang
Le Wang
XWXilu Wang
Xilu Wang
APAndrew M. Petros
Andrew M. Petros
ASAndrew J. Souers
Andrew J. Souers

1 August 2016 in Nature Chemical Biology
Verified
Journal Article
Closed access
ABAaron Boudreau
Aaron Boudreau
HPHans E Purkey
Hans E Purkey
AHAnna Hitz
Anna Hitz
KRKirk Robarge
Kirk Robarge
DPDavid Peterson
David Peterson
TOThomas O'Brien
Thomas O'Brien

17 June 2003 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
HRHossein Razavi
Hossein Razavi
SPSatheesh K. Palaninathan
Satheesh K. Palaninathan
EPEvan Powers
Evan Powers
RWR. Wiseman
R. Wiseman
HPHans E. Purkey
Hans E. Purkey
JKJeffery Kelly
Jeffery Kelly

2 May 2018 in Nature
Verified
Journal Article
Closed access
PDF file
HHHoangdung Ho
Hoangdung Ho
AMAnh Miu
Anh Miu
MAMary Kate Alexander
Mary Kate Alexander
NGNatalie K. Garcia
Natalie K. Garcia
AOAngela Oh
Angela Oh
CKChristopher M. Koth
Christopher M. Koth

27 October 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SPScott A. Peterson
Scott A. Peterson
TKThomas Klabunde
Thomas Klabunde
HLHilal A. Lashuel
Hilal A. Lashuel
HPHans Purkey
Hans Purkey
JSJames C. Sacchettini
James C. Sacchettini
JKJeffery Kelly
Jeffery Kelly
Insoluble protein fibrils resulting from the self-assembly of a conformational intermediate are implicated as the causative agent in several severe human amyloid diseases, including Alzheimer’s disease, familial amyloid polyneuropathy, and senile systemic amyloidosis. The latter two diseases are associated with transthyretin (TTR) amyloid fibrils, which appear to form in the acidic partial denaturing environment of the lysosome. Here we demonstrate that flufenamic acid (Flu) inhibits the conformational changes of TTR associated with amyloid fibril formation. The crystal structure of TTR complexed with Flu demonstrates that Flu mediates intersubunit hydrophobic interactions and intersubunit hydrogen bonds that stabilize the normal tetrameric fold of TTR. A small-molecule inhibitor that stabilizes the normal conformation of a protein is desirable as a possible approach to treat amyloid diseases. Molecules such as Flu also provide the means to rigorously test the amyloid hypothesis, i.e., the apparent causative role of amyloid fibrils in amyloid disease.

1 December 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EHEmily J. Hanan
Emily J. Hanan
MBMarie-Gabrielle Braun
Marie-Gabrielle Braun
RHRobert A. Heald
Robert A. Heald
CMCalum MacLeod
Calum MacLeod
CCConnie Chan
Connie Chan
SSSteven T. Staben
Steven T. Staben